KVUE · Industrials

Kenvue Inc.

Ranked earnings events from SEC filings, earnings calls, press releases and news. Full Picture: what to focus on this earnings window

News · 2026-08-07

• Acquisition / Partnership / DivestitureImportance 71 · Surprise 60
  Kimberly-Clark is pursuing a roughly $40 billion acquisition of Kenvue, with closing expected in the fourth quarter of 2026. The transaction would combine Kimberly-Clark’s consumer products portfolio with Kenvue brands…
• Market Demand TrendsImportance 31 · Surprise 32
  Kenvue delivered its third consecutive quarter of net and organic sales growth, with gains across the Self Care, Skin Health and Beauty, and Essential Health segments. Volume increased 0.7% year over year, described as…

10-Q · 2026-08-06

• Acquisition / Partnership / DivestitureImportance 75 · Surprise 60
  K-C agreed to acquire all outstanding Kenvue shares in a stock-and-cash merger approved by Kenvue’s Board on November 2, 2025. Kenvue shareholders will receive 0.14625 K-C common shares plus $3.50 cash per Kenvue…
• Senior Notes RedemptionImportance 64 · Surprise 42
  Kenvue issued a full-redemption notice for its 5.35% Senior Notes due 2026 on February 13, 2026. The company redeemed the entire $750 million aggregate principal amount on February 23, 2026, at par plus accrued and…
• Restructuring and Supply Chain TransformationImportance 57 · Surprise 50
  Kenvue’s Board approved the 2026 Restructuring Initiative on February 17, 2026 to optimize the operating model, transform the supply chain, reduce complexity, and improve operating efficiency. Six-month restructuring…
• DividendsImportance 55 · Surprise 32
  Kenvue paid $796 million of dividends during the six months ended June 28, 2026, compared with $785 million in the prior-year period. The company paid quarterly dividends of $0.2075 per share on February 25 and May 27,…
• Operating Cash Flow TrendsImportance 54 · Surprise 40
  Net cash flow from operating activities increased to $1.177 billion for the six months ended June 28, 2026, from $1.049 billion in the prior-year period, a $128 million or 12.2% increase. The improvement primarily…
• Segment ProfitabilityImportance 49 · Surprise 32
  Six-month segment adjusted operating income increased 9.4% to $2.105 billion from $1.924 billion, led by Skin Health and Beauty’s 46.9% increase to $354 million. Skin Health and Beauty benefited from favorable value…
• Market Demand TrendsImportance 49 · Surprise 32
  Essential Health segment net sales increased 3.5% to $2.4 billion for the six months ended June 28, 2026, while organic sales increased 1.3% excluding a 2.2% favorable foreign-exchange impact. Volume increased 1.7%,…
• Segment Revenue PerformanceImportance 49 · Surprise 32
  Essential Health Segment net sales increased to $2.4 billion for the six months ended June 28, 2026, from $2.3 billion in the prior-year period, up $82 million or 3.5%. Organic sales increased 1.3% after a 2.2%…
• Liquidity and Debt PositionImportance 49 · Surprise 6
  Kenvue held $1.110 billion of cash and cash equivalents as of June 28, 2026, while total debt was $8.480 billion. Liquidity included a $4.0 billion revolving credit facility expiring in March 2029 and a $4.0 billion…
• Income Tax Rate ChangesImportance 48 · Surprise 40
  The six-month provision for income taxes increased $36 million to $340 million because of higher pretax income and a stock-based compensation tax shortfall, partly offset by a lower effective tax rate. The worldwide…
• Supply Chain Tariff ImpactImportance 44 · Surprise 60
  Tariffs imposed on goods imported into the United States reduced Essential Health adjusted operating income during the six months ended June 28, 2026. The tariff impact partially offset benefits from volume-related…
• Gross Margin DriversImportance 43 · Surprise 32
  Six-month cost of sales increased 3.5% to $3.261 billion from $3.151 billion, while gross margin expanded 10 basis points to 58.5% from 58.4%. Supply-chain optimization benefits and favorable value realization more…
• Operating Expense TrendsImportance 43 · Surprise 32
  Six-month selling, general, and administrative expenses decreased $51 million, or 1.7%, to approximately $2.990 billion, reducing SG&A as a percentage of sales by 210 basis points to 38.0%. Restructuring savings and a…
• Supply Chain OptimizationImportance 37 · Surprise 42
  Supply chain optimization initiatives generated benefits in cost of sales and supported segment performance across Self Care, Skin Health and Beauty, and Essential Health. The initiatives partially offset input-cost…
• Product Launch and TransitionImportance 31 · Surprise 42
  Product innovation supported volume growth across Kenvue’s portfolio, including Digestive Health in the United States, major Skin Health and Beauty need states, Wound Care, and Baby Care. Skin Health and Beauty volume…
• Revenue Performance and MixImportance 28 · Surprise 32
  Six-month net sales increased 3.7% to $7.864 billion from $7.580 billion, with organic sales up 1.2% after a 2.5% favorable foreign-exchange impact. Price/mix contributed 1.0% and volume contributed 0.2%, driven by…
• Competition and Pricing PressureImportance 20 · Surprise 24
  Essential Health experienced declines in Oral Care largely attributable to competitive pressures. The segment also used increased strategic price investments across all regions, resulting in unfavorable value…
• Distribution Gains in Wound CareImportance 17 · Surprise 24
  Essential Health volume growth included distribution gains in Wound Care, largely attributable to the United States. Wound Care gains were one of the segment’s primary volume drivers alongside strong e-commerce…
• Digital Channel and Delivery GrowthImportance 10 · Surprise 6
  Strong e-commerce performance contributed to volume growth across all three reportable business segments in the quarter. E-commerce was particularly important for Self Care, where it partially offset lower…
• Geographic Market CommentaryImportance 10 · Surprise 6
  Latin America, EMEA, and Asia Pacific supported value realization through new pricing actions. Self Care demand was weaker in EMEA and Asia Pacific because of Digestive Health declines, although Smoking Cessation grew…

8-K · 2026-08-06

• Acquisition / Partnership / DivestitureImportance 75 · Surprise 60
  Kenvue entered into a definitive merger agreement on November 2, 2025 under which Kimberly-Clark will acquire all outstanding Kenvue common shares in a cash-and-stock transaction. Shareholders of both companies…
• Headcount / RestructuringImportance 46 · Surprise 42
  Kenvue’s Board approved the 2026 Restructuring Initiative on February 17, 2026 to optimize the operating model, transform the supply chain, reduce complexity, and improve operating efficiency. The initiative is…
• Guidance / OutlookImportance 44 · Surprise 60
  Kenvue will not provide forward-looking guidance for 2026 because of its pending transaction with Kimberly-Clark. Management stated that first-half 2026 results met or exceeded expectations across key metrics. The…
• Liquidity and Debt PositionImportance 42 · Surprise 14
  Cash and cash equivalents totaled $1.1 billion as of June 28, 2026, unchanged from December 28, 2025. Total debt was $8.5 billion at both June 28, 2026 and December 28, 2025. Reported net debt improved to $7.4 billion…
• Income Tax Rate ChangesImportance 38 · Surprise 58
  The second-quarter effective tax rate fell to 23.7% from 28.6% year over year, reducing the rate by 4.9 percentage points. The adjusted effective tax rate declined to 22.9% from 26.9%, a 4.0-point decrease. Kenvue…
• Market Demand TrendsImportance 37 · Surprise 32
  Kenvue reported organic sales growth across all three segments, with Skin Health and Beauty up 3.7%, Essential Health up 1.1%, and Self Care up 0.6%. Skin Health and Beauty volume increased 1.0%, while Essential Health…
• Operating Cash Flow TrendsImportance 34 · Surprise 30
  Six-month 2026 operating cash flow increased to $1.2 billion from $1.0 billion in the prior-year period. The improvement was driven by higher net income, partly offset by increased use of working capital. Free cash…
• Product Launch and TransitionImportance 31 · Surprise 42
  The FDA approved Tylenol® with Naproxen, an OTC fixed-dose combination of acetaminophen and naproxen sodium. The product combines 650 mg of acetaminophen with 220 mg of naproxen sodium, begins working in under 30…
• Regulatory Approval MilestonesImportance 31 · Surprise 42
  The U.S. Food and Drug Administration approved Tylenol with Naproxen, Kenvue’s fixed-dose OTC combination of 650 mg acetaminophen and 220 mg naproxen sodium. The product was supported by eight clinical studies and…
• Revenue Performance and MixImportance 30 · Surprise 14
  Second-quarter 2026 net sales increased 3.0% year over year to $3,955 million, comprising 1.6% organic growth and a 1.4% foreign-currency benefit. Skin Health and Beauty was the fastest-growing segment, with sales up…
• Inflation, Tariffs and FXImportance 25 · Surprise 32
  Kenvue said second-quarter gross profit margin declined to 58.2% from 58.9% year over year, primarily reflecting inflation, tariffs, and unfavorable transactional foreign exchange. These pressures were partially offset…
• Geographic Market CommentaryImportance 20 · Surprise 24
  Self Care organic sales grew in North America, EMEA, and Asia Pacific, including a return to organic growth in the U.S., Kenvue’s largest market. Skin Health and Beauty organic sales grew across every region, led by…
• Gross Margin DriversImportance 18 · Surprise 14
  Second-quarter gross profit margin declined to 58.2% from 58.9% in the prior-year period, while adjusted gross margin declined to 60.2% from 60.9%. The margin pressure primarily reflected inflation, tariffs, and…
• Operating Margin DriversImportance 18 · Surprise 14
  Second-quarter operating income margin decreased to 17.7% from 18.0% year over year, and adjusted operating margin decreased to 22.1% from 22.7%. The decline reflected lower gross and adjusted gross margins and a…
• Competition and Market ShareImportance 17 · Surprise 24
  Zyrtec® continued to gain share and strengthen its leadership position in U.S. Allergy. Pepcid® continued to outperform the Digestive Health market, while Nicorette® outperformed the Smoking Cessation category across…
• Distribution ChannelsImportance 17 · Surprise 24
  Strong eCommerce momentum supported Self Care growth in the U.S. and Skin Health and Beauty growth globally. Essential Health also reported strong eCommerce momentum and U.S. distribution gains. Kenvue cited eCommerce,…

News · 2026-08-06

• Kimberly-Clark AcquisitionImportance 71 · Surprise 60
  Kenvue is undergoing a proposed acquisition by Kimberly-Clark valued at approximately $40 billion. Third-party reports expect the combination to close in the fourth quarter of 2026, subject to completion of the…
• Restructuring Program ChargesImportance 40 · Surprise 42
  Kenvue anticipates significant pre-tax charges in 2026 from a restructuring program. The program is intended to improve operations and reduce costs amid inflationary and tariff-related margin pressure. Third-party…
• Regulatory Approval MilestoneImportance 38 · Surprise 60
  The U.S. Food and Drug Administration approved Tylenol with Naproxen, an over-the-counter fixed-dose combination. The approval creates a regulatory milestone for Kenvue’s Self Care portfolio. The digest does not…
• Guidance and OutlookImportance 37 · Surprise 42
  Kenvue did not provide future guidance in its second-quarter reporting. Third-party coverage attributed the omission to the pending combination with Kimberly-Clark. Management nevertheless characterized first-half 2026…
• Revenue Performance and MixImportance 31 · Surprise 32
  Kenvue’s second-quarter 2026 net sales increased 3.0% year over year to $3.955 billion, compared with an analyst estimate of approximately $3.97 billion to $3.99 billion. Growth was broad-based across the Self Care,…
• Market Demand TrendsImportance 31 · Surprise 32
  Kenvue delivered its third consecutive quarter of net and organic sales growth, with gains across the Self Care, Skin Health and Beauty, and Essential Health segments. Volume increased 0.7% year over year, described as…
• Gross Margin DriversImportance 25 · Surprise 32
  Kenvue’s second-quarter gross profit margin declined year over year as inflation, tariffs, and foreign-exchange costs increased pressure on product economics. Adjusted operating income margin also decreased despite…

News · 2026-08-04

• Acquisition / Partnership / DivestitureImportance 71 · Surprise 60
  Kimberly-Clark is pursuing a roughly $40 billion acquisition of Kenvue, with closing expected in the fourth quarter of 2026. The transaction would combine Kimberly-Clark’s consumer products portfolio with Kenvue brands…
• Headcount / RestructuringImportance 40 · Surprise 42
  Kenvue expects significant pretax charges during 2026 from a restructuring program designed to improve operations and reduce costs. The program is intended to generate operational efficiencies while the company manages…
• Revenue Performance and MixImportance 31 · Surprise 32
  Kenvue’s second-quarter 2026 net sales increased 3.0% year over year to $3.955 billion, compared with an analyst estimate of approximately $3.97 billion to $3.99 billion. Growth was broad-based across the Self Care,…
• Dividend DeclarationImportance 13 · Surprise 6
  Kenvue declared a quarterly dividend of $0.21 per share following its second-quarter results. The payment corresponds to an annualized dividend yield of approximately 4.4% based on the reported share price. The…